Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Considerations for Prescribing Avacopan for ANCA-Associated Vasculitis

Michele B. Kaufman, PharmD, BCGP  |  Issue: December 2021  |  October 27, 2021

On Oct. 7, the U.S. Food & Drug Administration (FDA) approved avacopan for the adjunctive treatment of adults with severe active anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (i.e., granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy, such as glucocorticoids. Avacopan is an oral complement 5a receptor (C5aR) inhibitor, which was studied in the ADVOCATE trial published earlier this year (NCT02994927).1 Whether the treatment could replace glucocorticoids for some patients has not been well established.2,3

The Rheumatologist previously reported on the FDA’s Arthritis Advisory Committee narrow vote to support the approval of avacopan to treat adults with active ANCA-associated vasculitis.4 The approval of avacopan was held up due to controversial study results on whether the agent itself was responsible for the beneficial effects in treating ANCA-associated vasculitis.5

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

According to the manufacturer, avacopan is intended to be used as a steroid replacement, with similar efficacy but an improved safety profile compared with glucocorticoids. Advisory members felt the study design and the non-study-supplied glucocorticoids used in this single study made it unclear what benefit was due to avacopan vs. the glucocorticoids. There were also safety concerns because the study was not long term, minorities were poorly represented and certain adverse effects occurred (e.g., rhabdomyolysis, angioedema, hepatotoxicity).2

In its approval of avacopan, the FDA is requiring the manufacturer to perform a post-marketing study of at least five years’ duration to evaluate safety outcomes, assess signals of hepatotoxicity and drug-induced liver injury and assess serious hypersensitivity reactions, including angioedema and anaphylaxis. The deadline for finalization for this study protocol is May 2022, with final results due September 2031.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Additionally, ChemoCentryx Inc., must conduct a clinical drug interaction study to further delineate the pharmacokinetics of continuous avacopan dosing at steady state, with food and with CYP3A4 substrates. The goal of this study is to aid in determining appropriate dosing strategies for the administration of avacopan. The deadline for finalization for this study protocol is April 2022 with final results February 2023.

Considerations

Avacopan will be available in 10 mg capsules, with a recommended dosage of 30 mg—three 10 mg capsules—taken twice daily with food. The warning and precautions for the treatment include:

  • Hepatotoxicity, including transaminase elevations and hepatobiliary events, which can be serious or life-threatening. Therefore, it’s recommended physicians obtain a liver panel prior to a patient starting avacopan, and every four weeks thereafter for the first six months of treatment. Subsequent monitoring for hepatotoxicity should be continued as clinically indicated;
  • Hypersensitivity reactions, including angioedema;
  • Hepatitis B reactivation; and
  • Serious, including fatal, infections. Patients should be closely monitored and properly treated for the development of signs of infection during and after treatment. The most common serious infections reported in clinical trials in patients treated with avacopan were pneumonia and urinary tract infection.

In clinical trials, the most common adverse reactions, which occurred in approximately 5% of patients, were an increase in blood creatinine, diarrhea, dizziness, fatigue, headache, hypertension, nausea, paresthesia, rash, upper abdominal pain and vomiting. Additionally, strong and moderate CYP3A4 enzyme inducers (e.g., rifampin) should be avoided while taking avacopan. When taking strong CYP3A4 enzyme inhibitors (e.g., itraconazole), the dose of avacopan should be reduced to 30 mg taken once daily.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021 Feb 18;384(7):599–604.
  2. FDA new drug application approval letter: Tavneos (avacopan). U.S. Food & Drug Administration. 2021 Oct 7.
  3. Tavneos (avacopan): Prescribing information. U.S. Food & Drug Administration. 2021 Oct.
  4. Hickman RJ. FDA’s Arthritis Advisory Committee narrowly endorses avacopan approval. www.the-rheumatologist.org. 2021 Aug 11.
  5. Arthritis Advisory Committee (AAC) meeting. U.S. Food & Drug Administration, Center for Drug Evaluation and Research. 2021 May 6.

Page: 1 2 | Multi-Page
Share: 

Filed under:Drug UpdatesVasculitis Tagged with:AAV FocusRheumANCA-Associated Vasculitisanti-neutrophil cytoplasmic antibodies (ANCA)avacopanFDAFDA approvalU.S. Food and Drug Administration (FDA)

Related Articles
    Sci Writers / shutterstock.com

    FDA’s Arthritis Advisory Committee Narrowly Endorses Avacopan Approval

    August 11, 2021

    On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…

    Study: Can Avacopan Replace Steroids in ANCA-Associated Vasculitis?

    May 13, 2021

    SewCream / shutterstock.com A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Sonis Photography / shutterstock.com Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis,…

    FDA Approves Avacopan for the Treatment of ANCA-Associated Vasculitis

    October 8, 2021

    On Oct. 8, ChemoCentryx Inc. announced that the U.S. Food & Drug Administration (FDA) has approved avacopan (TAVNEOS), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences